Paul Lamb, MD
Gastroenterology · Dothan, ALNPI 1386769404
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,900 of the $57,973 with a category attached, or 75.7%. AbbVie accounts for 83.1% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2019 at $44,110 and has fallen 90.7% since, to $4,109 in 2025. Among gastroenterology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 669 payments — averaging $86.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$48K
- Sanofi$2K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$725
- Ironwood Pharmaceuticals, Inc$462
- plus $4K from 33 others
Across 100 payments — averaging $12,013 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$589K
- Genentech, Inc.$451K
- Novartis$106K
- Amgen$37K
- Adare Pharmaceuticals, Inc.$18K
What the payments were for
- Consulting fees$1,2002%
- Speaking & faculty fees$43,90076%
- Travel & lodging$1,7853%
- Food & beverage$10,78719%
- Education$2740%
- Gifts$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$23,168
- ZENPEP$22,319
- VIBERZI$13,268
- Alinia$337
- EVIS EXERA lll COLONOVIDEOSCOPE$117
How this compares
$57,973 in reported general payments places this provider in the 95th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 16 | $430,471 |
| LinzessLinaclotide | 215 | $178,755 |
| XifaxanRifaximin | 48 | $164,527 |
| CreonLipase/Protease/Amylase | 56 | $153,768 |
| ZenpepLipase/Protease/Amylase | 28 | $87,735 |
| IbsrelaTenapanor Hcl | 39 | $68,362 |
| TrulancePlecanatide | 73 | $61,236 |
| RelistorMethylnaltrexone Bromide | 16 | $38,229 |
| Colesevelam Hcl | 177 | $23,216 |
| Dexlansoprazole DrDexlansoprazole | 68 | $16,663 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 185 | $12,057 |
| Ursodiol | 49 | $12,042 |
| Omeprazole | 574 | $10,391 |
| Budesonide DrBudesonide | 27 | $9,508 |
| Budesonide EcBudesonide | 34 | $8,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,605 | $430,47116 claims |
| AbbVieLinzess, Creon | $48,193 | $332,523271 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Relistor | $1,163 | $263,992137 claims |
| Aimmune Therapeutics, Inc.Zenpep | $109 | $87,73528 claims |
| Ardelyx, Inc.Ibsrela | $437 | $68,36239 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $108 | $4,99629 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $725 | $3,83312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Dothan
- Travis RutlandDothan$302K
- Samuel TarwaterDothan$12K
- George NelsonDothan$11K
- Scott SarrelsDothan$10K
- Robert AlbaresDothan$9K
- William McLaughlinDothan$8K
- Robert ShafferBirmingham$1M
- Jack DipalmaMobile$903K
- Phillip HendersonMobile$462K
- Viplove SenadhiMontgomery$282K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.